These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 3121275)
1. Encainide. A review of its pharmacological properties and therapeutic efficacy. Brogden RN; Todd PA Drugs; 1987 Nov; 34(5):519-38. PubMed ID: 3121275 [TBL] [Abstract][Full Text] [Related]
2. Encainide: a new antiarrhythmic agent. Wehmeyer AE; Thomas RL Drug Intell Clin Pharm; 1986 Jan; 20(1):9-13. PubMed ID: 3080301 [TBL] [Abstract][Full Text] [Related]
3. Encainide: its electrophysiologic and antiarrhythmic effects, pharmacokinetics, and safety. Tordjman T; Estes NA Pharmacotherapy; 1987; 7(5):149-63. PubMed ID: 3124082 [TBL] [Abstract][Full Text] [Related]
4. The clinical use of class IC antiarrhythmic drugs. Abi Samra F J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias. Winkle RA; Peters F; Kates RE; Tucker C; Harrison DC Circulation; 1981 Aug; 64(2):290-6. PubMed ID: 6788400 [TBL] [Abstract][Full Text] [Related]
7. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide. Harrison DC; Kates RE; Quart BD Am J Cardiol; 1986 Aug; 58(5):66C-73C. PubMed ID: 3092622 [TBL] [Abstract][Full Text] [Related]
8. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents. Chase SL; Sloskey GE Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276 [TBL] [Abstract][Full Text] [Related]
9. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide. Winkle RA; Peters F; Kates RE; Harrison DC Am J Cardiol; 1983 Apr; 51(7):1182-8. PubMed ID: 6404150 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia. Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of encainide in supraventricular arrhythmias. Pool PE Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():573-7. PubMed ID: 2125835 [TBL] [Abstract][Full Text] [Related]
13. Spectrum of antiarrhythmic response to encainide. Duff HJ; Roden DM; Carey EL; Wang T; Primm RK; Woosley RL Am J Cardiol; 1985 Nov; 56(13):887-91. PubMed ID: 3933319 [TBL] [Abstract][Full Text] [Related]
14. Encainide: a new and potent antiarrhythmic. Somberg JC; Zanger D; Levine E; Tepper D Am Heart J; 1987 Oct; 114(4 Pt 1):826-35. PubMed ID: 3116833 [No Abstract] [Full Text] [Related]
15. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092 [TBL] [Abstract][Full Text] [Related]
16. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial. Anderson JL J Clin Pharmacol; 1990 Nov; 30(11):981-9. PubMed ID: 2122984 [TBL] [Abstract][Full Text] [Related]
17. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Kreeger RW; Hammill SC Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116 [TBL] [Abstract][Full Text] [Related]
18. Response to encainide of refractory ventricular tachycardia: clinical application of assays for parent drug and metabolites. Anderson JL; Stewart JR; Johnson TA; Lutz JR; Pitt B J Cardiovasc Pharmacol; 1982; 4(5):812-9. PubMed ID: 6182414 [TBL] [Abstract][Full Text] [Related]